- Home
- OPTT vs CANF Comparison
OPTT vs CANF Comparison
Compare OPTT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTT
- CANF
- Stock Information
- Founded
- OPTT 1984
- CANF 1994
- Country
- OPTT United States
- CANF Israel
- Employees
- OPTT N/A
- CANF N/A
- Industry
- OPTT Electric Utilities: Central
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- OPTT Utilities
- CANF Health Care
- Exchange
- OPTT Nasdaq
- CANF Nasdaq
- Market Cap
- OPTT 17.2M
- CANF 14.4M
- IPO Year
- OPTT 2007
- CANF N/A
- Fundamental
- Price
- OPTT $0.16
- CANF $2.67
- Analyst Decision
- OPTT
- CANF Strong Buy
- Analyst Count
- OPTT 0
- CANF 2
- Target Price
- OPTT N/A
- CANF $14.00
- AVG Volume (30 Days)
- OPTT 4.1M
- CANF 144.0K
- Earning Date
- OPTT 12-11-2024
- CANF 11-15-2024
- Dividend Yield
- OPTT N/A
- CANF N/A
- EPS Growth
- OPTT N/A
- CANF N/A
- EPS
- OPTT N/A
- CANF N/A
- Revenue
- OPTT $5,554,000.00
- CANF $667,000.00
- Revenue This Year
- OPTT N/A
- CANF $356.93
- Revenue Next Year
- OPTT N/A
- CANF N/A
- P/E Ratio
- OPTT N/A
- CANF N/A
- Revenue Growth
- OPTT 68.81
- CANF N/A
- 52 Week Low
- OPTT $0.12
- CANF $1.81
- 52 Week High
- OPTT $0.57
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- OPTT 45.61
- CANF 66.63
- Support Level
- OPTT $0.14
- CANF $1.87
- Resistance Level
- OPTT $0.17
- CANF $2.84
- Average True Range (ATR)
- OPTT 0.01
- CANF 0.20
- MACD
- OPTT 0.00
- CANF 0.09
- Stochastic Oscillator
- OPTT 64.33
- CANF 81.72
About OPTT Ocean Power Technologies Inc.
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).